You are here: Home: Meet The Professors Vol. 1 2004: Case 5: Select publications
 |
| Select publications: First-line endocrine therapy in metastatic disease |
 |
Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003;8(4):335-41. Abstract
Carlson RW, Henderson IC. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat 2003;80(Suppl 1):19-26; discussion 27-8. Abstract
Howell A et al. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat 2003;82(3):215-22. Abstract
Howell SJ et al. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 2004;18(1):47-66. Abstract
Ingle JN. Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 2004;10(Suppl 1):362-7. Abstract
Jones SE. Fulvestrant: An estrogen receptor antagonist that downregulates the estrogen receptor. Semin Oncol 2003;30(5 Suppl 16):14-20. Abstract
Lake DE, Hudis C. Aromatase inhibitors in breast cancer: An update. Cancer Control 2002;9(6):490-8. Abstract
Ligibel JA, Winer EP. Clinical differences among the aromatase inhibitors. Clin Cancer Res 2003;9(1 Pt 2):473S-9S. Abstract
Mouridsen H et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21(11):2101-9. Abstract
Mouridsen H, Gershanovich M. The role of aromatase inhibitors in the treatment of metastatic breast cancer. Semin Oncol 2003;30(4 Suppl 14):33-45. Abstract
Mouridsen HT et al. Challenges in the endocrine management of breast cancer. Breast 2003;12(Suppl 2):2-19. Abstract
Paridaens R et al. Mature results of a randomized Phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14(9):1391-8. Abstract
Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther 2002;24(Suppl C):43-57. Abstract
Piccart M et al. Oestrogen receptor downregulation: An opportunity for extending the window of endocrine therapy in advanced breast cancer. Ann Oncol 2003;14(7):1017-25. Abstract
Pritchard KI. Endocrine therapy of advanced disease: Analysis and implications of the existing data. Clin Cancer Res 2003;9(1 Pt 2):460S-7S. Abstract
Simons WR et al. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin Ther 2003;25(11):2972-87. Abstract
Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer: Aromatase inhibitor or antioestrogen? Br J Cancer 2004;90(1):20-5. Abstract
|
